Zafgen Inc (NASDAQ:ZFGN) has been downgraded to Hold in a report by Zacks Investment Research today.
- Updated: September 21, 2016
Yesterday Zafgen Inc (NASDAQ:ZFGN) traded 3.59% higher at $3.43. The company’s 50-day moving average is $3.13 and its 200-day moving average is $5.42. The last closing price is down -36.15% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time period. 1,045,984 shares of the stock traded hands, up from an average trading volume of 627,566
Zacks Investment Research has downgraded Zafgen Inc (NASDAQ:ZFGN) to Hold in a report released on 9/21/2016.
Previously on 03/10/2016, RBC Capital Markets reported on Zafgen Inc (NASDAQ:ZFGN) reduced the target price from $21.00 to $19.00. At the time, this indicated a possible upside of 1.95%.
See Chart Below
Zafgen Inc has a with a one year low of $2.90 and a one year high of $44.98 Zafgen Inc’s market capitalization is currently $0.
In addition to Zacks Investment Research reporting its target price, a total of 7 brokerages have released a ratings update on ZFGN. The one year target is $22.14 with two firms rating the stock a strong buy, two equity analysts rating the stock a buy, 3 analysts rating the company a hold, zero brokerages rating the company a underperform, and lastly zero equity analysts rating the company a sell.
General Information About Zafgen Inc (NASDAQ:ZFGN)
Zafgen, Inc. is a biopharmaceutical company. The Company is focused on improving the health and well-being of patients affected by obesity and complex metabolic disorders. The Company's lead product candidate, Beloranib, is a twice-weekly subcutaneous injection being developed for the treatment of multiple indications, including severe obesity in rare diseases, such as Prader-Willi syndrome (PWS) and hypothalamic injury-associated obesity (HIAO), including craniopharyngioma-associated obesity. Beloranib is in Phase III stage of development for PWS. It is also developing ZGN-839, a liver-targeted methionine aminopeptidase 2 (MetAP2) inhibitor, for the treatment of nonalcoholic steatohepatitis (NASH) and abdominal obesity, as well as other second-generation MetAP2 inhibitors for the treatment of severe obesity. It is also evaluating additional MetAP2 inhibitors beyond Beloranib as a development candidate for the treatment of severe obesity in the general population.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.